DOCSLIB.ORG

Recombinant Antibodies Against Clostridium Difficile Toxin A. Phd Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recombinant Antibodies Against Clostridium Difficile Toxin A. Phd Thesis Almdni, Sabir M.S. (2013) Recombinant antibodies against Clostridium difficile Toxin A. PhD thesis. http://theses.gla.ac.uk/4727/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] Recombinant antibodies against Clostridium difficile Toxin A College of Medical Veterinary and Life Sciences School of Life Sciences February 2013 Sabir M.Shakir Almdni Supervisor: Dr R. Aitken A thesis submitted for the degree of Doctor of Philosophy Abstract Clostridium difficile is a major cause of nosocomial intestinal infection. The pathogen possesses two potent toxins, Toxin A and Toxin B, both of which contribute to diarrhoea, intestinal inflammation and tissue damage. Antibiotics are effective against the disease, however around 20 % of patients on treatment relapse after the termination of antibiotic therapy. The binding of Toxin A to a receptor on human intestinal epithelial cells initiates disease: this is considered the starting point from which the toxin elicits its effect. One feature of the carboxy-terminal domain of Toxin A is the presence of repeating units of amino acids that form a series of binding sites able to recognise disaccharides and trisaccharides on glycolipid and glycoprotein receptor molecules. Antibody response against the toxin can protect against C. difficile disease and efforts to generate vaccines have focused upon the carboxy-terminal, receptor binding domain. The aims of this project were to use phage display to isolate recombinant antibodies against those features of the carboxy-terminal domain of Toxin A thought to be responsible for receptor-binding and to assess if the antibodies were capable protecting against the action of Toxin A. Using published crystallographic data that has shown the interaction of Toxin A and trisaccharide, a region of about 113 amino acids from the carboxy- terminal region of Toxin A was expressed as a fusion to maltose-binding protein. The MBP fusion protein was expressed, purified on amylose resin, and characterised. The fusion protein was then used to isolate single chain antibodies from the Tomlinson libraries of scFvs, a synthetically diversified 2 phage display library of single scaffold human antibodies. Conventional bio- panning methods were used in which the MBP fusion protein was bound to a plastic surface and the phage display libraries were pre-mixed with native MBP to inhibit the isolation of anti-MBP antibodies. Progressive enrichment of scFvs through 3 rounds of selection was observed. Those scFvs that showed strongest reaction against the target protein in ELISA but failed to react with native MBP were sequenced, expressed as soluble antibodies and purified on nickel chelating columns. While the resulting panel of scFvs showed similarities of sequence, none were identical. All were reactive with native, full-length Toxin A and appeared to bind to conformational (nonlinear) epitopes. Cross-reaction with Toxin B from C. difficile was also evident. A panel of truncation mutants were generated from the MBP fusion protein and using these in ELISA with the scFvs, reactivity appeared to be directed to features of a long repeat sequence of Toxin A. To assay whether the isolated scFvs possessed biological activity of significance, in vitro and in vivo protection assays were established. For experiments in vitro, the action of Toxin A upon cultured Vero cells was studied. Native Toxin A triggered a conversion of the cells from stellate to rounded morphology. When cells were exposed to 100 ng of toxin, this effect was evident within 60 minutes; at a 10-fold lower dose, the minimum quantity to which a response was detectable, virtually all cells had undergone rounding within 2 h. When individual scFvs were mixed with 10 ng of Toxin A prior to addition to Vero cells, there was a consistent delay in cytopathic activity that extended to 5 h. In this assay, the percentage of cells that had retained their stellate morphology 5 h post-challenge was dependent on the scFv used. To quantify the potency of this neutralising activity, the amount of each scFv required to achieve 50% 3 protection during a 2 h challenge period was established. This revealed 3.5-fold difference between the most and the least effefctive scFv. The most potent scFv was used in an in vivo assay in which Toxin A was administered to the ligated intestinal loops of rats. Again, protective activity was evident. Overall, phage display technology enabled the assembly of a panel of scFv antibodies against the putative receptor binding site in the carboxy-terminal domain of Toxin A from C. difficile. The scFvs were able to protect against the cytopathic activity of Toxin A in vitro and in vivo and proposals are made about how these observations could be taken forward in a model of C. difficile infection that best mimics the human disease. 4 Table of Contents Chapter One Introduction ................................................................ 17 1.1 Overview ......................................................................... 17 1.2 Pathogenesis .................................................................... 19 1.3 Epidemiology .................................................................... 28 1.4 Risk factor ....................................................................... 29 1.4.1 Toxin function ............................................................. 30 1.4.2 Toxin expression regulation ............................................. 32 1.5 Strains of importance .......................................................... 34 1.6 Diagnosis ......................................................................... 39 1.7 Treatment and therapeutics .................................................. 41 1.7.1 Antibiotic therapy ......................................................... 42 1.7.2 Non-antibiotic therapy ................................................... 45 1.8 Antibodies ....................................................................... 51 1.9 Phage display .................................................................... 55 1.9.1 Antibody formats .......................................................... 57 1.9.2 Affinity maturation ....................................................... 58 1.9.3 Antibody libraries ......................................................... 59 1.9.4 Naïve libraries ............................................................. 61 1.9.5 Immune libraries .......................................................... 62 1.9.6 Synthetic libraries ......................................................... 62 1.9.7 The choice of phage coat protein ....................................... 63 1.9.8 Some limitations of phage display ...................................... 64 1.9.9 Selection in antibody phage display .................................... 65 1.9.10 Screening of phage displayed antibodies and antibody expression 67 1.10 Overall aims of the project ................................................... 68 Chapter Two Protein expression and purification .................................... 70 2.1 Introduction ..................................................................... 70 2.1.1 Toxin A binding to its receptor .......................................... 70 2.1.2 General strategy ........................................................... 71 2.1.3 Maltose-binding protein .................................................. 71 2.1.4 Aims for the experiments ................................................ 72 2.2 Materials and methods ......................................................... 73 2.2.1 Construction, expression and purification of maltose-binding protein (MBP) fusions ................................................................ 73 2.2.1.1 Confirmation of sequence .......................................... 73 2.2.1.2 Primer design for putative binding site of TcdA-MBP fusion .. 74 2.2.1.3 Polymerase chain reaction (PCR) .................................. 75 2.2.1.4 Preparation of pCG806 and target insert ......................... 77 2.2.1.5 Ligation and transformation ........................................ 79 2.2.1.6 Analysis of transformants ........................................... 80 2.2.1.7 Sequencing ............................................................ 81 2.2.1.8 Bacterial growth, induction and expression of the native MBP and fusions proteins ............................................................... 81 2.2.1.9 Purification of the proteins using affinity chromatography ... 81 2.2.1.10 SDS-PAGE analysis of purified proteins ........................... 82 2.2.1.11 Electroblotting of the purified proteins .......................... 83 2.2.1.12 Protein assay ......................................................... 84 2.2.2 Construction of truncation mutants from the putative binding site of TcdA-MBP fusion .................................................................. 84 2.2.2.1 Construction of MBP-SR1, MBP-LR, MBP-SR2 and MBP-SR3
Load more

Recommended publications
  • Using Peptide-Phage Display to Capture Conditional Motif-Based Interactions
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1716 Using peptide-phage display to capture conditional motif-based interactions GUSTAV SUNDELL ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-513-0433-5 UPPSALA urn:nbn:se:uu:diva-359434 2018 Dissertation presented at Uppsala University to be publicly examined in B42, BMC, Husargatan 3, Uppsala, Friday, 19 October 2018 at 09:15 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Doctor Attila Reményi (nstitute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary). Abstract Sundell, G. 2018. Using peptide-phage display to capture conditional motif-based interactions. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1716. 87 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0433-5. This thesis explores the world of conditional protein-protein interactions using combinatorial peptide-phage display and proteomic peptide-phage display (ProP-PD). Large parts of proteins in the human proteome do not fold in to well-defined structures instead they are intrinsically disordered. The disordered parts are enriched in linear binding-motifs that participate in protein-protein interaction. These motifs are 3-12 residue long stretches of proteins where post-translational modifications, like protein phosphorylation, can occur changing the binding preference of the motif. Allosteric changes in a protein or domain due to phosphorylation or binding to second messenger molecules like Ca2+ can also lead conditional interactions. Finding phosphorylation regulated motif-based interactions on a proteome-wide scale has been a challenge for the scientific community.
    [Show full text]
  • Development of a Phage Display Library for Discovery of Antigenic Brucella Peptides Jeffrey Williams Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2018 Development of a phage display library for discovery of antigenic Brucella peptides Jeffrey Williams Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Microbiology Commons Recommended Citation Williams, Jeffrey, "Development of a phage display library for discovery of antigenic Brucella peptides" (2018). Graduate Theses and Dissertations. 16896. https://lib.dr.iastate.edu/etd/16896 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Development of a phage display library for discovery of antigenic Brucella peptides by Jeffrey Williams A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Microbiology Program of Study Committee: Bryan H. Bellaire, Major Professor Steven Olsen Steven Carlson The student author, whose presentation of the scholarship herein was approved by the program of study committee, is solely responsible for the content of this thesis. The Graduate College will ensure this thesis is globally accessible and will not permit alterations after a degree is conferred. Iowa State University
    [Show full text]
  • Phage Display Libraries for Antibody Therapeutic Discovery and Development
    antibodies Review Phage Display Libraries for Antibody Therapeutic Discovery and Development Juan C. Almagro 1,2,* , Martha Pedraza-Escalona 3, Hugo Iván Arrieta 3 and Sonia Mayra Pérez-Tapia 3 1 GlobalBio, Inc., 320, Cambridge, MA 02138, USA 2 UDIBI, ENCB, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomas, Delegación Miguel Hidalgo, Ciudad de Mexico 11340, Mexico 3 CONACyT-UDIBI, ENCB, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomas, Delegación Miguel Hidalgo, Ciudad de Mexico 11340, Mexico * Correspondence: [email protected] Received: 24 June 2019; Accepted: 15 August 2019; Published: 23 August 2019 Abstract: Phage display technology has played a key role in the remarkable progress of discovering and optimizing antibodies for diverse applications, particularly antibody-based drugs. This technology was initially developed by George Smith in the mid-1980s and applied by John McCafferty and Gregory Winter to antibody engineering at the beginning of 1990s. Here, we compare nine phage display antibody libraries published in the last decade, which represent the state of the art in the discovery and development of therapeutic antibodies using phage display. We first discuss the quality of the libraries and the diverse types of antibody repertoires used as substrates to build the libraries, i.e., naïve, synthetic, and semisynthetic. Second, we review the performance of the libraries in terms of the number of positive clones per panning, hit rate, affinity, and developability of the selected antibodies. Finally, we highlight current opportunities and challenges pertaining to phage display platforms and related display technologies.
    [Show full text]
  • Revealing Protein Structures: a New Method for Mapping Antibody Epitopes
    Revealing protein structures: A new method for mapping antibody epitopes Brendan M. Mumey Brian W. Bailey Edward A. Dratz Department of Computer NIH/NlAAA/DlCBWLMBB Department of Chemistry and Science Fluorescence Studies Biochemistry Montana State University Park 5 Building Montana State University Bozeman, MT 59717-3880 12420 Parklawn Dr. MSC Bozeman, MT 59717-3400 [email protected] 8115 [email protected] Bethesda, MD 20892-8115 [email protected] ABSTRACT cells [9] and each protein has a unique folded structure. Whenever A recent idea for determining the three-dimensional structure of a the 3-D folding structure of linear protein sequences can be de- protein uses antibody recognition of surface structure and random termined this information has provided fundamental insights into peptide libraries to map antibody epitope combining sites. Anti- mechanisms of action that are often extremely useful in drug de- bodies that bind to the surface of the protein of interest can be sign. Traditional methods of protein structure determination re- used as “witnesses” to report the structure of the protein as follows: quire preparation of large amounts of protein in functional form, Proteins are composed of linear polypeptide chains that come to- which often may not be feasible. Attempts are then made to grow gether in complex spatial folding patterns to create the native pro- 3-D crystals of the proteins of interest for structure determination tein structures and these folded structures form the binding sites by x-ray diffraction, however, obtaining crystals of sufficient qual- for the antibodies. Short amino acid probe sequences, which bind ity is still an art and may not be possible [24, 251.
    [Show full text]
  • Monitoramento Em Biotecnologia Desenvolvimento Científico E Tecnológico
    Centro de Gestão e Estudos Estratégicos Ciência, Tecnologia e Inovação Monitoramento em Biotecnologia Desenvolvimento científico e tecnológico 3° Relatório Volume II - Patentes e Países Depositantes Coordenação Adelaide Antunes Rio de Janeiro Março, 2005 MONITORAMENTO EM BIOTECNOLOGIA Desenvolvimento científico e tecnológico 3° Relatório Volume II Patentes e Países Depositantes Executor: Sistema de Informação sobre a Indústria Química (SIQUIM) Escola de Química (EQ) Universidade Federal do Rio de Janeiro (UFRJ) Março / 2005 2 A Biotecnologia tem sido destacada como tecnologia portadora do futuro e consequentemente, com alto componente de desenvolvimento econômico e social, em vários países, principalmente nos últimos anos. O estudo "Monitoramento em Biotecnologia" encomendado pelo CGEE ao SIQUIM/EQ/UFRJ, permite visualizar a dinâmica de P,D&I desta área, a diversidade de atores envolvidos e o forte escopo de atuação em desenvolvimentos que impactam fortemente "Saúde e Qualidade de vida", bem como a "Agricultura e Meio ambiente", por meio de desenvolvimento acelerado de publicações científicas e de patentes nos Temas e/ou Termos tratados neste estudo. Reforça-se, então, que este estudo representa um instrumento importante de apoio à decisão aos stakeholders atuantes na área, pois permite priorizar ações concernentes ao desenvolvimento e estímulo ao uso sustentável da biodiversidade, à segurança biológica e à produção de bioprodutos, biodrogas, transgênicos. Monitoramento em Biotecnologia SIQUIM/EQ/UFRJ e CGEE 3 EQUIPE: Coordenação Geral:
    [Show full text]
  • Phage Display
    Chem. Rev. 1997, 97, 391−410 391 Phage Display George P. Smith* and Valery A. Petrenko Division of Biological Sciences, University of Missouri, Columbia, Missouri 65211 Received January 2, 1997 (Revised Manuscript Received January 23, 1997) Contents more, and that in a degree which exceeds all computation.”1 I. In Vitro Evolution of Chemicals 391 II. Phage-Display Libraries as Populations of 392 Replicable, Mutable Chemicals But ever since Darwin we have come to understand that the exquisite “watches” of the living world are A. Phage-Display Vectors 392 fashioned by an altogether different process. As B. How Foreign Peptides Are Displayed on 393 Richard Dawkins writes in his compelling book on Filamentous Phages evolution, natural selection “does not plan for the C. Types of Phage-Display Systems 394 future. It has no vision, no foresight, no sight at all. III. Types of Displayed Peptides and Proteins 394 If it can be said to play the role of watchmaker in IV. Selection 397 nature, it is the blind watchmaker.”2 A. General Principles 397 Imagine, then, the applied chemist, not as designer B. Affinity Selection 397 of molecules with a particular purpose, but rather C. Selection for Traits Other than Affinity 399 as custodian of a highly diverse population of chemi- D. Enrichment of Specific Sequence Motifs 399 cals evolving in vitro as if they were organisms V. Exploring the Fitness Landscape 400 subject to natural selection. A chemical’s “fitness” A. Sequence Space, Fitness Landscapes, and 400 in this artificial biosphere would be imposed by the Sparse Libraries custodian for his or her own ends.
    [Show full text]
  • Large-Scale Interaction Profiling of PDZ Domains Through Proteomic Peptide-Phage Display Using Human and Viral Phage Peptidomes
    Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes Ylva Ivarssona,1, Roland Arnolda, Megan McLaughlina,b, Satra Nima, Rakesh Joshic, Debashish Raya, Bernard Liud, Joan Teyraa, Tony Pawsond,2, Jason Moffata,b, Shawn Shun-Cheng Lic, Sachdev S. Sidhua,c,3, and Philip M. Kima,b,e,3 bDepartment of Molecular Genetics, eDepartment of Computer Science, aDonnelly Centre, University of Toronto, Toronto, ON, Canada M5S 3E1; cDepartment of Biochemistry, Western University, London, ON, Canada N6A 5C1; and dLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada M5G 1X5 Edited* by William F. DeGrado, University of California at San Francisco School of Pharmacy, San Francisco, CA, and approved January 6, 2014 (receivedfor review July 2, 2013) The human proteome contains a plethora of short linear motifs advantage of microarray-based oligonucleotide synthesis to con- (SLiMs) that serve as binding interfaces for modular protein domains. struct custom-made peptide-phage libraries for screening peptide– Such interactions are crucial for signaling and other cellular processes, protein interactions, an approach we call proteomic peptide- but are difficult to detect because of their low to moderate phage display (ProP-PD) (Fig. 1). This process is similar in con- affinities. Here we developed a dedicated approach, proteomic cept to the method for autoantigen discovery recently proposed peptide-phage display (ProP-PD), to identify domain–SLiM interac- by Larman et al. (12). In this earlier work, a T7 phage display tions. Specifically, we generated phage libraries containing all hu- library comprising 36-residue overlapping peptides covering all man and viral C-terminal peptides using custom oligonucleotide ORFs in the human genome was used to develop a phage im- microarrays.
    [Show full text]
  • Strategies for Selecting Membrane Protein-Specific Antibodies Using Phage Display with Cell-Based Panning
    antibodies Review Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning Mohamed A. Alfaleh 1,2,* ID , Martina L. Jones 1,3,* ID , Christopher B. Howard 1,3,4 and Stephen M. Mahler 1,3 1 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia; [email protected] (C.B.H.); [email protected] (S.M.M) 2 Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia 3 Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland 4072, Australia 4 Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland 4072, Australia * Correspondence: [email protected] (M.A.A.); [email protected] (M.L.J.); Tel.: +61-733-463-178 (M.L.J.) Academic Editor: Dimiter S. Dimitrov Received: 14 June 2017; Accepted: 7 July 2017; Published: 5 August 2017 Abstract: Membrane proteins are attractive targets for monoclonal antibody (mAb) discovery and development. Although several approved mAbs against membrane proteins have been isolated from phage antibody libraries, the process is challenging, as it requires the presentation of a correctly folded protein to screen the antibody library. Cell-based panning could represent the optimal method for antibody discovery against membrane proteins, since it allows for presentation in their natural conformation along with the appropriate post-translational modifications. Nevertheless, screening antibodies against a desired antigen, within a selected cell line, may be difficult due to the abundance of irrelevant organic molecules, which can potentially obscure the antigen of interest.
    [Show full text]
  • Immunohistochemistry Antibodies
    IMMUNOHISTOCHEMISTRY ANTIBODIES HYBRIDOMA & PHAGE DISPLAY Technologies Project Strategy & Specifications Target Typology Applications: Immunohistochemistry (IHC) . Virus, bacteria, chemical compounds, haptens, etc. Frozen sections . Proteins (intracellular, membrane, post-translational . Paraffin-embedded sections (IHC-P, modifications, etc.) formalin-fixed, paraffin-embedded slides . Peptides (design, synthesis and conjugation) or FFPE slides) Initial Materials and Project Constraints BIOTEM offers a platform entirely dedicated . Available material (quantity, purity) to the development of functional monoclonal . Immunogenicity / Toxicity antibodies in IHC with a particularly high . Cross reaction and specificity success rate for paraffin-embedded samples. Timelines Exclusiveness BIOTEM IHC Peptide Profiler® To address the challenge of IHC-P antibodies, BIOTEM has developed an exclusive software called the IHC Peptide Profiler®. This software has been designed to generate first-class peptides to be used as immunogens in IHC-P antibody projects. Peptides generated by the software are fully suitable with any downstream technologies (Hybridoma and/or Phage Display). The software integrates complex algorithms which allow to sort out optimal peptides in a 3-steps process: 1- Modelisation of target altered structure in the FFPE environment 2- Primary peptide design 3- Final peptide selection and ranking All peptides generated during the primary design are further analyzed and ranked based on specific IHC-P criteria as well as more conventional and applicable parameters such as antigenicity, immunogenicity and solubility. The results can be extracted and summarized in a user friendly file which allows convenient selection of the final peptide candidates. IHC Protein Formulations Available only from BIOTEM, the IHC-specific antigen formulations that are designed to subtly modify proteins in order to obtain immunogens that mimic the targeted epitopes as they appear on IHC paraffin sections.
    [Show full text]
  • Chapter 2 Mrna Display
    8 Chapter 2 mRNA Display: Ligand Discovery, Interaction Analysis and Beyond This work has been adapted from the following publication: Takahashi, T.T., Austin, R.J. and Roberts, R.W. mRNA display: ligand discovery, interaction analysis and beyond. (2003) Trends Biochem Sci 28, 159-165. 9 Abstract In vitro peptide and protein selection using mRNA display* enables the discovery and directed evolution of new molecules from combinatorial libraries. These selected molecules can serve as tools to control and understand biological processes, enhance our understanding of molecular interactions, and potentially treat disease in therapeutic applications. In mRNA display, mRNA molecules are covalently attached to the peptide or protein they encode. These mRNA-protein fusions enable in vitro selection of peptide and protein libraries of more than 1013 different sequences. mRNA display has been used to discover novel peptide and protein ligands for RNA, small molecules, and proteins, as well as to define cellular interaction partners of proteins and drugs. In addition, several unique applications are possible with mRNA display, including self-assembling protein chips and library construction with unnatural amino acids, and chemically modified peptides. *mRNA display has been referred to as mRNA-protein fusions (1), in vitro virus and in vitro virus virion (2), and PROfusionTM technology (3). 10 Introduction Functional approaches, such as in vitro selection, currently provide the best means available for isolating peptides and proteins with desired chemical or biochemical properties. Over the last decade, display technologies have been essential tools in the discovery of peptide and protein ligands and in delineating in vivo interaction partners. The phage (4) and ribosome display systems (5) have been principally used for discovery, while the yeast two-hybrid method (6) has been used for in vivo interaction analysis.
    [Show full text]
  • Circulation of Fluorescently Labelled Phage in a Murine Model
    viruses Article Circulation of Fluorescently Labelled Phage in a Murine Model Zuzanna Ka´zmierczak 1,2,* , Joanna Majewska 2 , Magdalena Milczarek 3 , Barbara Owczarek 2 and Krystyna D ˛abrowska 2 1 Research and Development Center, Regional Specialist Hospital, Kamie´nskiego73a, 51-154 Wroclaw, Poland 2 Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland; [email protected] (J.M.); [email protected] (B.O.); [email protected] (K.D.) 3 Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Interactions between bacteriophages and mammals strongly affect possible applications of bacteriophages. This has created a need for tools that facilitate studies of phage circulation and deposition in tissues. Here, we propose red fluorescent protein (RFP)-labelled E. coli lytic phages as a new tool for the investigation of phage interactions with cells and tissues. The interaction of RFP-labelled phages with living eukaryotic cells (macrophages) was visualized after 20 min of co-incubation. RFP-labeled phages were applied in a murine model of phage circulation in vivo. Phages administered by three different routes (intravenously, orally, rectally) were detected through the course of time. The intravenous route of administration was the most efficient for phage delivery Citation: Ka´zmierczak, Z.; Majewska, J.; Milczarek, M.; to multiple body compartments: 20 min after administration, virions were detected in lymph Owczarek, B.; D ˛abrowska, K. nodes, lungs, and liver; 30 min after administration, they were detectable in muscles; and 1 h after Circulation of Fluorescently Labelled administration, phages were detected in spleen and lymph nodes.
    [Show full text]
  • Phage Display Selection on Whole Cells Yields a Small Peptide Specific for HCV Receptor Human CD81
    Cell research (2003); 13(6): 473-479 http://www.cell-research.com Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81 JIE CAO1, PING ZHAO1, XIAO HUI MIAO2, LAN JUAN ZHAO1, LI JUN XUE1, ZHONG TIAN QI1,* 1Department of Microbiology, Second Military Medical University, Shanghai 200433, China E-mail: [email protected] 2Department of Infectious Diseases, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China ABSTRACT The human CD81 (hCD81), the most recently proposed receptor of hepatitis C virus (HCV), can especifically bind to HCV envelope glycoprotein 2 (E2). In this study, hCD81-expressing murine NIH/3T3 cells were used to select hCD81-binding peptides from a phage displayed nonapeptide library (PVIII9aaCys). Eighteen of the 75 clones selected from the library showed specific binding to the hCD81-expressing NIH/3T3 cells by enzyme linked immunosorbent assay (ELISA) and competitive inhibition test. Twelve out of the 18 clones shared the amino acid motif SPQYWTGPA. Sequence comparison of the motif showed no amino acid homology with the native HCV E2. The motif-containing phages could competitively inhibit the ability of HCV E2 binding to native hCD81-expressing MOLT-4 cells, and induce HCV E2 specific immune response in vivo. These results suggest that the selected motif SPQYWTGPA should be a mimotope of HCV E2 to bind to hCD81 molecules. Our findings cast new light on developing HCV receptor antagonists. Key words: viral receptor, hepatitis C virus, cell-based selection, hCD81-binding peptide, phage display. INTRODUCTION liferation, activation and differentiation[4-6]. Although the mechanism involving in the cell entry of HCV was not Hepatitis C virus (HCV), a most common causative known clearly, human CD81 (hCD81) was considered as agent for post-transfusional hepatitis, is a positive- a putative HCV receptor[7-10].
    [Show full text]